CABG PATCH TRIAL--DATA COORDINATING CENTER
CABG贴片试验--数据协调中心
基本信息
- 批准号:3553523
- 负责人:
- 金额:$ 59.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-03-12 至 1997-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The CABG Patch Trial is a multicenter, randomized controlled clinical
trial to test the hypothesis that implantable cardioverter defibrillator
(ICD) therapy will improve survival in coronary heart disease patients
at high risk of death, especially arrhythmic death, i.e., patients with
severe left ventricular dysfunction who also have a marker of arrhythmic
risk (positive signal averaged ECG). To address this question, patients
with coronary heart disease will be enrolled if they are having coronary
artery bypass graft surgery, are less than 80 years of age, have left
ventricular ejection fraction less than 0.36, and have a positive signal
averaged ECG. This group is similar to the patients who already have had
a sustained ventricular arrhythmia and therefore have an indication for
ICD treatment under current guidelines. Also, the group has a high
probability of experiencing death during follow-up. The treatment and
control groups are well matched for another important aspect of chronic
coronary heart disease - risk for ischemic events. Having both groups
revascularized at the beginning of the trial has the potential advantage
of sharpening the endpoint, i.e., a smaller proportion of all deaths are
expected to be ischemic, and a larger proportion are expected to be
arrhythmic, a pathophysiology that is addressed superbly by the treatment
under study. Enrolled patients will be randomized during surgery to
receive an ICD or not. We plan to randomize 800 patients, half to the
control group and half to the ICD group. Patients will be followed for
an average of three years after randomization. The CABG Patch Trial has
80%-85% power to detect a hypothesized 40% reduction in the 40-month
hazard rate for all-cause mortality in the ICD treated group. In
addition, The CABG Patch Trial will: document any morbidity of ICD
treatment; evaluate the effects of ICD therapy on quality of life; and
compare the health care costs of ICD treatment with those in the control
group. In the narrowest interpretation, the results will apply to high
risk coronary heart disease patients undergoing CABG surgery. Also, the
results should apply substantially to patients who satisfy the current
indications for ICD treatment and to some other high risk coronary heart
disease patients who have not yet had an arrhythmic event.
冠状动脉搭桥术贴片试验是一项多中心、随机对照的临床试验
试验验证植入型心律转复除颤器的假设
(ICD)治疗将提高冠心病患者的存活率
死亡风险高,特别是心律失常死亡,即
严重的左心功能不全,同时也有心律失常的标志
风险(阳性信号平均心电图)。为了解决这个问题,病人们
如果患有冠状动脉疾病,将被登记为冠心病患者
动脉搭桥手术,年龄都不到80岁,都离开了
心室射血分数小于0.36,并有积极的信号
平均心电图。这一群体与已经接受治疗的患者相似
持续性室性心律失常,因此有迹象表明
在当前指南下进行ICD治疗。此外,这组人有很高的
随诊期间发生死亡的概率。治疗和治疗
对照组在慢性病的另一个重要方面表现得很好
冠心病--发生缺血性事件的风险。两组都有
在试验开始时重新血运重建具有潜在的优势
锐化终点,即所有死亡的较小比例是
预计是缺血的,预计更大比例的是
心律失常,一种通过治疗得到极佳治疗的病理生理学
正在研究中。入选的患者将在手术期间随机进行
是否收到ICD。我们计划对800名患者进行随机抽样,其中一半是
对照组,一半给ICD组。将对患者进行跟踪治疗
随机化后平均三年。冠状动脉旁路移植术贴片试验
在40个月内检测到假设减少40%的能力为80%-85%
ICD治疗组全因死亡率的风险率。在……里面
此外,CABG贴片试验将:记录ICD的任何发病率
评估ICD治疗对生活质量的影响;以及
ICD治疗与对照组的医疗费用比较
一群人。在最狭义的解释中,结果将适用于高
接受冠脉搭桥术的冠心病高危患者。另外,
结果应实质上适用于符合当前标准的患者
ICD治疗和其他一些高危冠心病的适应症
尚未发生心律失常事件的疾病患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN THOMAS BIGGER其他文献
JOHN THOMAS BIGGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN THOMAS BIGGER', 18)}}的其他基金
Developing Flexible EHR Plug-ins to Re-Engineer Clinical Care and Research Workfl
开发灵活的 EHR 插件以重新设计临床护理和研究工作
- 批准号:
7950139 - 财政年份:2010
- 资助金额:
$ 59.41万 - 项目类别:
Developing Flexible EHR Plug-ins to Re-Engineer Clinical Care and Research Workfl
开发灵活的 EHR 插件以重新设计临床护理和研究工作
- 批准号:
8316324 - 财政年份:2010
- 资助金额:
$ 59.41万 - 项目类别:
Developing Flexible EHR Plug-ins to Re-Engineer Clinical Care and Research Workfl
开发灵活的 EHR 插件以重新设计临床护理和研究工作
- 批准号:
8114209 - 财政年份:2010
- 资助金额:
$ 59.41万 - 项目类别:
CABG PATCH TRIAL--ADMINISTRATIVE AND CLINICAL CENTERS
CABG 补片试验——行政和临床中心
- 批准号:
2647449 - 财政年份:1993
- 资助金额:
$ 59.41万 - 项目类别:
CABG PATCH TRIAL--ADMINISTRATIVE AND CLINICAL CENTERS
CABG 补片试验——行政和临床中心
- 批准号:
2224203 - 财政年份:1993
- 资助金额:
$ 59.41万 - 项目类别:
CABG PATCH TRIAL--ADMINISTRATIVE AND CLINICAL CENTERS
CABG 补片试验——行政和临床中心
- 批准号:
2224205 - 财政年份:1993
- 资助金额:
$ 59.41万 - 项目类别:
CABG PATCH TRIAL--ADMINISTRATIVE AND CLINICAL CENTERS
CABG 补片试验——行政和临床中心
- 批准号:
2658808 - 财政年份:1993
- 资助金额:
$ 59.41万 - 项目类别:
相似海外基金
From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
- 批准号:
MR/Y013050/1 - 财政年份:2024
- 资助金额:
$ 59.41万 - 项目类别:
Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
- 批准号:
495575 - 财政年份:2023
- 资助金额:
$ 59.41万 - 项目类别:
Operating Grants
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
- 批准号:
2884930 - 财政年份:2023
- 资助金额:
$ 59.41万 - 项目类别:
Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 59.41万 - 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
- 批准号:
10855627 - 财政年份:2023
- 资助金额:
$ 59.41万 - 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
- 批准号:
10895949 - 财政年份:2023
- 资助金额:
$ 59.41万 - 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
- 批准号:
10891325 - 财政年份:2023
- 资助金额:
$ 59.41万 - 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
- 批准号:
10761602 - 财政年份:2023
- 资助金额:
$ 59.41万 - 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
- 批准号:
10758129 - 财政年份:2023
- 资助金额:
$ 59.41万 - 项目类别: